Design, synthesis and biological evaluation of novel hydroxamic acids bearing artemisinin skeleton

Abstract

A series of novel hydroxamic acids bearing artemisinin skeleton was designed and synthesized. Some compounds in this series exhibited moderate inhibition against the whole cell HDAC enzymes. Especially, compound 6g displayed potent cytotoxicity against three human cancer cell lines, including HepG2 (liver cancer), MCF-7 ( breast cancer) and HL-60 (leukemia cancer), with IC50 values of 2.50, 2.62 and 1.28 mu g/mL, respectively. Docking studies performed with two potent compounds 6a and 6g using Autodock Vina showed that both compounds bound to HDAC2 with relatively high binding affinities from -7.1 to 7.0 kcal/mol compared to SAHA (-7.4 kcal/mol). It was found in this research that most of the target compounds seemed to be more cytotoxic toward blood cancer cells (HL-60) than liver (HepG2), and breast (MCF-7) cancer cells. (C) 2016 Elsevier Inc. All rights reserved.